Liposomal Amphotericin B–Associated Cardiac Arrest: Case Report and Literature Review

Liposomal amphotericin B (L-AmB) was developed with the intent to minimize the adverse effects associated with amphotericin B deoxycholate, especially nephrotoxicity. Although there has been a substantial decrease in adverse effects with L-AmB compared with its predecessor, there is a small body of evidence suggesting its association with cardiovascular adverse events. We report a case of L-AmB-associated cardiac arrest in a patient with preexisting cardiac-related disease states. In addition, we review currently available literature regarding cardiac-related adverse events associated with L-AmB. When the Naranjo Adverse Drug Reaction Probability Scale was applied to this case, the probability of association was determined as possible. This case adds to a small but important body of literature regarding L-AmB–associated cardiotoxicity. Moreover, a review of the available literature indicates that providers should be aware of the potential for cardiac adverse events with L-AmB. Correspondence to: Marcus Tad Autry, PharmD, BCPS, PGY2 Ambulatory Care Pharmacy Residency, College of Pharmacy, University of Oklahoma, 1122 NE 13th St, Suite 2301A, Oklahoma City, OK 73117. E-mail: Marcus-Autry@ouhsc.edu. The authors have no funding or conflicts of interest to disclose. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2JMMCtZ